Evaluation of the Causes and Disease Processes of Chronic Lung Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6564 participants

Study Classification

OBSERVATIONAL

Study Start Date

1984-11-18

Study Completion Date

2019-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

1. Develop a better understanding of the causes and disease processes involved in disorders of the lungs
2. Identify patients eligible to participate in other P-CCMB research studies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

NCT02055222

Pulmonary Fibrosis Lung Disease

COMPLETED

Early Risk Predictors For Chronic Pulmonary Disease

NCT00005281

Asthma Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease

COMPLETED

Role of Genetic Factors in the Development of Lung Disease

NCT00001532

Cystic Fibrosis Pulmonary Fibrosis Tuberous Sclerosis +2 more

RECRUITING

Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals

NCT00001462

Emphysema Lung Diseases, Obstructive Alpha 1-Antitrypsin Deficiency

COMPLETED

Evaluation and Treatment of Patients With Lung Disease Not Participating in Research

NCT00001621

Pulmonary Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Pulmonary Patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Symptoms consistent with pulmonary disease.

May have family history of lung disease.

Patients with diseases of organs with known association with lung disease.

Ranging in age from 7 to 90 years old.

Pregnant and nursing women may participate in minimal risk procedures